piperacillin/tazobactam wh innrennslisstofn, lausn 4 g/0,5 g
williams & halls ehf. - piperacillinum natríum; tazobactamum natríum - innrennslisstofn, lausn - 4 g/0,5 g
kefzol stungulyfs-/innrennslisstofn, lausn 1 g
stada nordic aps. - cefazolinum natríum - stungulyfs-/innrennslisstofn, lausn - 1 g
ambisome liposomal innrennslisstofn, ördreifa 50 mg
gilead sciences ireland uc* - amphotericinum b inn - innrennslisstofn, ördreifa - 50 mg
spevigo
boehringer ingelheim international gmbh - spesolimab - psoriasis - Ónæmisbælandi lyf - spevigo is indicated for the treatment of flares in adult patients with generalised pustular psoriasis (gpp) as monotherapy.
lacosamide adroiq
extrovis eu ltd. - lacosamíð - flogaveiki - antiepileptics, - lacosamide adroiq is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy. lacosamide adroiq is indicated as adjunctive therapyin the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy. in the treatment of primary generalised tonic-clonic seizures in adults, adolescents and children from 4 years of age with idiopathic generalised epilepsy.
ultomiris
alexion europe sas - ravulizumab - blóðrauði, ofsakláði - valdar ónæmisbælandi lyf - paroxysmal nocturnal haemoglobinuria (pnh)ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with pnh:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5. atypical haemolytic uremic syndrome (ahus)ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with ahus who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5. generalized myasthenia gravis (gmg)ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gmg who are anti-acetylcholine receptor (achr) antibody-positive. neuromyelitis optica spectrum disorder (nmosd)ultomiris is indicated in the treatment of adult patients with nmosd who are anti-aquaporin 4 (aqp4) antibody-positive (see section 5. ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (ahus) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.
zometa
phoenix labs unlimited company - zoledronic sýru, zoledronic sýru einhýdrat - cancer; fractures, bone - lyf til að meðhöndla beinsjúkdóma - fyrirbyggja beinagrind atburðum tengdum (sjúkleg beinbrot, hrygg þjöppun, geislun eða skurðaðgerð á að beinum, eða æxli völdum álíka) í sjúklinga með langt illkynja þar bein;meðferð æxli völdum álíka (tih);fyrirbyggja beinagrind atburðum tengdum (sjúkleg beinbrot, hrygg þjöppun, geislun eða skurðaðgerð á að beinum, eða æxli völdum álíka) í sjúklinga með langt illkynja þar bein;meðferð æxli völdum álíka (tih);fyrirbyggja beinagrind atburðum tengdum (sjúkleg beinbrot, hrygg þjöppun, geislun eða skurðaðgerð á að beinum, eða æxli völdum álíka) í fullorðinn sjúklinga með langt illkynja þar bein;meðferð fullorðinn sjúklinga með æxli völdum álíka (tih).
azithromycin stada filmuhúðuð tafla 500 mg
stada arzneimittel ag - azithromycinum mónóhýdrat - filmuhúðuð tafla - 500 mg
morphasol vet stungulyf, lausn 4 mg/ml
animedica gmbh* - butorphanolum tartrat - stungulyf, lausn - 4 mg/ml
ontozry
angelini pharma s.p.a - cenobamate - flogaveiki - antiepileptics, - adjunctive treatment of focal-onset seizures with or without secondary generalisation in adult patients with epilepsy who have not been adequately controlled despite a history of treatment with at least 2 anti-epileptic medicinal products.